Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afinitor plus paclitaxel and carboplatin in first-line advanced pulmonary large-cell neuroendocrine carcinoma
2010-022273-34Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2011
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus, paclitaxel and carboplatin in Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC) and neuroendocrine carcinoma (NEC), sponsored by Novartis. Primary endpoint: Proportion of subjects progression-free at Month 3. Started Jan 2011; status: completed.
02
Drugs
everolimuspaclitaxelcarboplatin
03
Conditions
Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on 2010-022273-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022273-34.